Published in Cancer Weekly, May 26th, 1997
A collaborative effort between researchers from Vion Pharmaceuticals, Connecticut, and Yale University School of Medicine, Connecticut, has resulted in several studies (see subsequent stories in this issue) regarding an attenuated form of S. typhimurium as an anticancer agent. L.M. Zheng, representing colleagues from both institutions, presented evidence American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California that S. typhimurium infection inhibits tumor metastasis in vivo.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.